A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17) is a research paper published in Antibodies (2024). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R01CA245081
National Institutes of Health
Grant: R41CA265624
National Institutes of Health
Grant: R42CA268138
National Institutes of Health
Grant: R44CA268138
National Institutes of Health
Grant: P30 CA138313
National Institutes of Health
Grant: 22-20-HOBB
National Institutes of Health
Grant: P20GM130457
NIH/NCI
Grant: 1R41CA265624-01
Bispecific T cell engagers for the treatment of pancreatic ductal adenocarcinoma
National Institutes of Health
Grant: 4R44CA268138-02
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma
National Institutes of Health
Grant: 5R01CA245081-05
Inhibitors of Oxidative Protein Folding For The Treatment of Cancer
National Institutes of Health
Grant: 1R42CA268138-01
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma
National Institutes of Health
Grant: 5P30CA138313-09
Medical University of South Carolina - Cancer Center Support Grant
National Institutes of Health
Grant: 3P20GM130457-02S1
CDLD Administrative Supplement for Equipment
Fields of Study
Keywords